Data support the safety and efficacy of dupilumab treatment for up to 5 years in adults with moderate to severe atopic dermatitis, confirming previous data demonstrating sustained efficacy with an acceptable safety profile. https://ja.ma/3Y1o4Hu
JAMA Dermatology
Book and Periodical Publishing
Chicago, Illinois 11,427 followers
A member of the JAMA Network, which includes JAMA, 11 specialty journals, and JAMA Network Open.
About us
JAMA Dermatology is published online weekly, every Wednesday, and in 12 print/online issues a year. The journal receives more than 7.2 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program. JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. The journal's acceptance rate is 10%. The median time to first decision is 4 days, and 47 days with review. The Journal Impact Factor is 10.9, one of the highest ranking among dermatology journals. All articles are published online first. Kanade Shinkai, MD, PhD, UCSF Department of Dermatology, San Francisco, California, is the editor in chief.
- Website
-
https://jamanetwork.com/journals/jamadermatology
External link for JAMA Dermatology
- Industry
- Book and Periodical Publishing
- Company size
- 5,001-10,000 employees
- Headquarters
- Chicago, Illinois
- Founded
- 1882
- Specialties
- Dermatology
Updates
-
Lebrikizumab, a new biologic medication, has comparable efficacy to dupilumab for the treatment of atopic dermatitis in adults. https://ja.ma/3xY866p
-
-
Cendakimab was effective, generally safe, and well-tolerated in patients with moderate to severe atopic dermatitis, finds this randomized clinical trial. https://ja.ma/469vBpG
-
-
Viewpoint compares 2 clinical trials involving immune checkpoint inhibitors in kidney transplant recipients. https://ja.ma/4cMoxSc
-
Case report describes a woman in her 30s who presented with cutaneous lesions since age of 2 to 3 years with erythema and pain on her nose, both cheeks, and ears when exposed to cold temperatures that progressed to nasal and auricular cartilage necrosis. https://ja.ma/3y31Bz1
-
-
Bed bugs are small parasitic insects that eat only one thing—human blood—and they get it only one way: by biting people. This Patient Page describes the symptoms, diagnosis, and treatment of bed bugs. https://ja.ma/4cwA4Fe
Bed Bugs
jamanetwork.com
-
Apart from recurrent infections, patients with chronic granulomatous disease (CGD) are prone to developing inflammatory complications. This study found 2 distinct inflammatory cutaneous presentations of CGD. https://ja.ma/4cXbDRb
-
-
Most viewed in the last 7 days from JAMA Dermatology: What is the global prevalence of seborrheic dermatitis and how do demographic variations affect its prevalence? https://ja.ma/3WjIKJB
-
-
Direct calcitonin gene-related peptide inhibition is associated with decreased rates of developing acne and rosacea compared with no inhibition (topiramate) or indirect inhibition (triptans) in patients experiencing migraines. https://ja.ma/4bCtlZ5
Calcitonin Gene-Related Peptide Inhibition and Development of Acne and Rosacea
jamanetwork.com
-
A healthy young male patient was referred to the department of dermatology for evaluation of a solitary painful scrotal ulceration that developed rapidly 48 hours before consultation. What is your diagnosis? https://ja.ma/3S568YN
-